BioPharma Resources

Drug Trial Radar · NCT07441460

A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer

A Randomized, Controlled, Open-label, Multicenter, Phase III Clinical Study to Evaluate the Efficacy and Safety of KN026 Combined With HB1801 and Chemotherapy Versus Trastuzumab Combined With Pertuzumab and Chemotherapy as Adjuvant Therapy in Resectable HER2-positive Breast Cancer

Last checked: Nov 19, 2026Latest source record: Apr 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,800 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,800

Planned (sponsor's estimate)

Start

Mar 6, 2026

Primary completion

Aug 7, 2034

Study completion Aug 7, 2035

Sponsor

Lead sponsor
Shanghai JMT-Bio Inc.Industry
Sponsor type
Industry
First posted
Mar 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, controlled, open-label, multicenter, Phase Ⅲ clinical study designed to compare the efficacy and safety of KN026 combined with HB1801 and chemotherapy versus trastuzumab combined with pertuzumab and chemotherapy as adjuvant therapy in participants with HER2-positive breast cancer.

Conditions

  • Resectable HER2-positive Breast Cancer

Interventions

  • KN026Drug

    In accordance with the protocol

  • HB1801Drug

    In accordance with the protocol

  • TrastuzumabDrug

    Intravenous infusion

  • PertuzumabDrug

    Intravenous infusion

  • DocetaxelDrug

    Intravenous infusion

  • EpirubicinDrug

    Intravenous infusion

  • DoxorubicinDrug

    Intravenous infusion

  • CyclophosphamideDrug

    Intravenous infusion

  • CarboplatinDrug

    Intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. iDFSTime frame: 5 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.